JERUSALEM, September 17, 2013 -- /PRNewswire/ --
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has been granted a patent from Russia's Federal Service for Intellectual Property, Patents and Trademarks (ROSPATENT) for the Company's invention, titled "Methods and Compositions for Oral Administrations of Proteins." The patent covers a core concept of the Company's technology for the oral delivery of drugs currently delivered via injection. Oral delivery can greatly improve patient compliance and outcomes.
This patent has also been granted in New Zealand, South Africa and China. Oramed's intellectual property portfolio now consists of nine issued patents and 26 patents pending.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently initiating Phase 2 clinical trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), with trials on healthy volunteers (Phase 1b) and T2DM patients (Phase 2a) underway. Oramed is also moving forward with clinical trials of ORMD-0801 for the treatment of type 1 diabetes. The company's corporate and R&D headquarters are based in Jerusalem.
For more information, the content of which is not part of this press release, please visit http://www.oramed.com.
Help employers find you! Check out all the jobs and post your resume.